Drug Development Consulting BidCo ApS: Financial statements 2022
CVR: 42287067
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Drug Development Consulting BidCo ApS (CVR 42287067) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 3,760,000 and a net result of DKK -11,831,000. Equity in the 2022 report amounted to DKK 71,831,000. The solvency ratio was 57.8%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 3,760,000
- Profit/Loss
- DKK -11,831,000
- Equity
- DKK 71,831,000
- Total Assets
- DKK 124,307,000
- Employees
- 1
Official annual report
Keep an eye on Drug Development Consulting BidCo ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Drug Development Consulting BidCo ApS has published its interim report for the period April 8, 2021 to December 31, 2021.
About Drug Development Consulting BidCo ApS
Drug Development Consulting BidCo ApS is a Danish company of the type Anpartsselskab based in Brøndby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of René Holmen Pedersen. The board consists of Niels Peder Nielsen (chair), Alejandra Maria Cristina Bonifacini Mørk, Rafael Natanek and Redmar Koene. The company is owned by Drug Development Consulting Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 5,875,000 and a net result of DKK -61,325,000 compared with DKK -13,215,000 the year before. Equity in the 2025 report amounted to DKK 32,493,000.
